Active Infection & Immunity

Manipulating tertiary lymphoid structures to modulate disease outcome

In plain English

AI plain-English summary

The body’s immune system sometimes builds its own miniature command centres inside diseased tissues, and researchers want to learn how to control them. These structures—called tertiary lymphoid structures—form spontaneously in organs affected by chronic inflammation, such as tumours or autoimmune lesions. Doctors have seen them correlate with both good and bad outcomes, but no one knows exactly how they assemble or what determines whether they help or harm. Current understanding borrows heavily from how lymph nodes form in embryos, yet the cells and signals involved in adult tissues are clearly different. This collaboration brings together three teams with complementary expertise to map the molecular cues that drive TLS formation across different diseases, including cancer. They will ask whether there are universal features shared across pathologies, and test whether manipulating these structures can shift the immune response toward a beneficial outcome. If successful, the work could open a new route to treating chronic inflammatory diseases and cancer—not by suppressing the immune system broadly, but by tuning the local micro-organs that shape its response. The research is fundamental: it aims to uncover basic rules of immune organisation, with future therapeutic applications contingent on what those rules turn out to be.

View original technical description
Chronic inflammation drives the formation of tertiary lymphoid structures (TLS) – a spectrum of ectopic lymphoid cell aggregates that can form within many tissues. Clinical observations correlate TLS to both pathological and beneficial adaptive immune responses in different disease states. However, much of our understanding of how TLS form is assumed from embryonic secondary lymphoid tissue development, despite clear differences in tissue sites, timing and cellular players involved. We still lack clear understanding of the molecular cues driving TLS formation across diverse tissues and inflammatory contexts. Furthermore, exactly how these tissue niches alter local immune function and disease progression remains to be determined. Our over-arching hypothesis is that TLS can be manipulated to improve disease outcome. We will test this and answer: 1_How does immune/stromal cell crosstalk generate a spectrum of TLS in cancer? 2_Are there universal features in TLS across different pathologies? 3_What immune functions are supported by the spectrum of TLS maturation states? 4_Can we exploit key features of TLS to modulate immune function in disease? Here, three research groups with distinct, but highly complementary expertise and experimental approaches will collaborate to discover why and how TLS form and the mechanisms through which they support specific immune functions.

View the original record at the funder ↗

Researchers

David Withers (EPMC Awardee)Menna Clatworthy (EPMC Awardee)Sophie Acton (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Tertiary lymphoid structures as novel tools for cancer immunotherapy
TLSmacs
Harnessing the lymphoid tissue niche to boost anti-tumour immunity
Investigating the structure and functional role of gut tertiary lymphoid organs in inflammation
Cellular communication in fibrosis: investigating the role of tissue-resident T cells in the human liver

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.